Aligning Cancer Healthcare System Readiness: Harmonizing EU Regulations and R&D

We all share a collective goal in healthcare: to create meaningful change and improve lives. Pragmatism can serve as the catalyst to bridge the gap between ideas and implementation.

When it comes to supporting individuals facing cancer, continuous evolution and innovation in clinical trials are essential. The landscape of oncology treatments is rapidly advancing, setting higher benchmarks to surpass the existing standard of care. With improved cancer prognoses and a focus on earlier detection and treatment, achieving significant overall survival (OS)* is becoming more time-intensive, and in some cases, the endpoint may not even be reached. Consequently, regulatory and reimbursement processes that hinge on OS data can delay or restrict patient access to groundbreaking, potentially life-saving therapies.¹

Addressing this challenge requires a shift in how we select and interpret clinical and biological endpoints. By evolving these approaches, we can expedite patient access to innovative treatments and further progress in personalized medicine.

“At Sanofi, we strive to modernize the treatment of cancer by working to bring new therapies for difficult-to-treat cancers.”

At Sanofi, our mission is to revolutionize cancer treatment by prioritizing the development of therapies for cancers that present significant treatment challenges. This journey involves focusing on areas where we can make the greatest impact. To achieve this, we actively collaborate with leading cancer research institutions, cooperative groups, biotech innovators, and public-private partnerships like the Paris-Saclay Cancer Cluster. Together, these partnerships are driving progress in oncology research and development.

Our efforts are centered on addressing unmet needs in specific types of cancers, including select hematologic malignancies like multiple myeloma (MM), acute myeloid leukemia (AML), and certain lymphomas, as well as select solid tumors such as gastrointestinal and lung cancers. Through these targeted initiatives, we aim to advance treatment options and improve outcomes for patients worldwide.